Jun 2026 (Q2 FY26) — Aug 13, 2026
Euroseas Q2 FY26 — Strong Charter Coverage and Newbuilding Program Expansion
Read the full callEuroseas earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 38.3 | Quarterly, as filed | Quarter to Dec 2021 | Revenue from operations as filed. No quarter a year earlier is in the series, so no change is shown. | |
| Operating margin | 62.6 | Operating profit / revenue | Quarter to Dec 2021 | For the quarter; a change is in percentage points. No quarter a year earlier is in the series, so no change is shown. | |
| Net profit | 22.8 | Quarterly, as filed | Quarter to Dec 2021 | Profit after tax as filed. No quarter a year earlier is in the series, so no change is shown. |
Price
1Y: $56.2 on 14 Oct 2025 → $67.45. High $79.39 (30 Jul 2026), low $52.51 (21 Jan 2026).
Overview
Call summaries
Euroseas Q2 FY26 — Strong Charter Coverage and Newbuilding Program Expansion
Read the full callEvery analysed call
Financials
| Line item | Dec 2021 |
|---|---|
| Sales | 38 |
| Operating profit | 24 |
| Operating margin | 62.6% |
| Other income | -1 |
| Interest | 1 |
| Net profit | 23 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -230 | -234 | -230 | -188 | -93 | 8 | 104 | 205 |
| Total liabilities | 44 | 99 | 75 | 145 | 160 | 158 | 228 | 237 |
| Fixed assets | 49 | 116 | 98 | 176 | 217 | 268 | 443 | 466 |
| Total assets | 67 | 127 | 111 | 221 | 329 | 425 | 591 | 700 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | 3 | 2 | 53 | 114 | 130 | 128 | 141 |
| Cash from investing | — | -56 | 16 | -74 | -87 | -102 | -169 | -15 |
| Cash from financing | 0 | 45 | -18 | 47 | -27 | 5 | 57 | -23 |
| Net cash flow | 5 | -7 | 0 | 25 | -0 | 33 | 16 | 103 |
| Capital expenditure | -0 | -56 | -1 | — | — | — | — | — |
| Free cash flow | -1 | -52 | 2 | — | — | — | — | — |
13 filings between Apr 14, 2026 and Oct 2, 2026.
Purchases
$235.9K
7 purchases by 2 insiders
Sales
$485.5K
6 sales by 4 insiders
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Aslidis Anastasios | $70.8K | $357.3K | Oct 2, 2026 |
| Pittas Aristeidis P | $165.1K | $35.1K | Oct 2, 2026 |
| Pariaros Symeon | — | $75.0K | Sep 1, 2026 |
| Karmiri Stefania | — | $18.0K | Apr 16, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Pittas Aristeidis P Director | Purchase | 525 | $37.3K |
| Oct 2, 2026 | Pittas Aristeidis P Director | Purchase | 525 | $37.3K |
| Oct 2, 2026 | Aslidis Anastasios Chief Financial Officer | Sale | 1,000 | $72.1K |
| Oct 1, 2026 | Aslidis Anastasios Chief Financial Officer | Sale | 4,000 | $285.2K |
| Sep 1, 2026 | Pariaros Symeon Chief Administrative Officer | Sale | 950 | $75.0K |
| Aug 27, 2026 | Pittas Aristeidis P Director | Purchase | 375 | $28.4K |
| Aug 27, 2026 | Pittas Aristeidis P Director | Purchase | 375 | $28.4K |
| Jun 11, 2026 | Pittas Aristeidis P Director | Purchase | 250 | $16.8K |
| Jun 11, 2026 | Pittas Aristeidis P Director | Purchase | 250 | $16.8K |
| Apr 16, 2026 | Karmiri Stefania Corporate Secretary | Sale | 250 | $18.0K |
| Apr 14, 2026 | Aslidis Anastasios Chief Financial Officer | Purchase | 1,000 | $70.8K |
| Apr 14, 2026 | Pittas Aristeidis P Vice Chairman | Sale | 250 | $17.6K |
| Apr 14, 2026 | Pittas Aristeidis P Vice Chairman | Sale | 250 | $17.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow EUROSEAS LTD. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading